Skip to main content
Premium Trial:

Request an Annual Quote

Novartis Taps Galapagos to Design siRNA-Based Cellular Assays for Target Validation

NEW YORK, July 6 (GenomeWeb News) - Galapagos said today that its Galadeno genomics division has entered into an agreement with Novartis Pharmaceuticals UK to design cellular assays using its SilenceSelect gene knock-down platform.


Galadeno will provide technology, reagents, and support to assist Novartis researchers in validating drug targets by analyzing protein function in human primary cells. Galadeno will receive payments related to the research services and its SilenceSelect technology.


Additional financial terms were not provided.


Galapagos said that Galadeno's SilenceSelect technology can knock down more than 4,000 human proteins by producing short interfering RNA in human cells.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.